The first and only approved treatment
for recurrent pericarditis
ARCALYST® (rilonacept) is the first and only FDA-approved treatment indicated for the treatment of recurrent pericarditis and the reduction in risk of recurrence.
ARCALYST, an IL-1 soluble decoy receptor, targets the underlying mechanism that drives inflammation in recurrent pericarditis. It is indicated to be used in adults and children 12 years and older.
ARCALYST at a glance
The Risk of Recurrence
Learn more about the prevalence of recurrent pericarditis, the underlying cause of recurrent inflammation, and why reducing the risk of recurrence matters for your patients.
(hazard ratio: 0.04; p<0.0001).1
The efficacy and safety of ARCALYST were evaluated in RHAPSODY, a Phase 3, double-blind, placebo-controlled, event-driven, randomized withdrawal study (N=61).
The primary efficacy endpoint was time to first adjudicated pericarditis recurrence in the randomized withdrawal period.
Get familiar with the safety profile, dosing and administration, and treatment duration of ARCALYST.
Access and resources
Kiniksa OneConnect offers patients support for injection training, financial assistance, and treatment logistics.